Hyperlipidemic Response to Endotoxin - a Part of the Host-defence Mechanism

References

• Liao W, Florén C H. Endotoxin cytokines and hyperlipidemia. Scand J Gastroenterol 1993; 28: 97–103
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Feingold K R. Tumor necrosis factor, cytokines, and the hyperlipidemia of infection. Trends Endocrinol Metab 1991; 2: 213–219
   PubMed Web of Science ®Google Scholar
• Rudbach J A, Johnson A G. Restoration of endotoxin activity following alteration by plasma. Nature 1964; 202: 811–812
   PubMed Web of Science ®Google Scholar
• Levin J, Tomasulo P A, Oser R S. Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med 1970; 75: 903–911
   PubMed Web of Science ®Google Scholar
• Ulevitch R J, Johnston A R, Weinstein D B. New function for high density lipoproteins: their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 1979; 64: 1516–1524
   PubMed Web of Science ®Google Scholar
• Ulevitch R J, Johnston A R, Weinstein D B. New function for high density lipoproteins: isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67: 827–837
   PubMed Web of Science ®Google Scholar
• Munford R S, Hall C L, Lipton J M, Dietschy J M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest 1982; 70: 877–888
   PubMed Web of Science ®Google Scholar
• Van Lenten B J, Fogelman A M, Haberland M E, Ewards P A. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1986; 83: 2704–2708
   PubMed Web of Science ®Google Scholar
• Harris H S, Eichbaum E B, Kane J P, Rapp J H. Detection of endotoxin in triglyceride-rich lipoproteins in vitro. J Lab Clin Med 1991; 118: 186–193
   PubMed Web of Science ®Google Scholar
• Eichbaum E B, Harris H S, Kane J P, Rapp J H. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991; 51: 413–416
   PubMed Web of Science ®Google Scholar
• Emancipator K, Csako G, Elin R J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60: 596–601
   PubMed Web of Science ®Google Scholar
• Berger D, Schleich S, Seidelmann M, Beger H G. Correlation between endotoxin-neutralizing capacity of plasma as tested by the limulus-amebocyte-lysate and plasma protein levels. FEBS Lett 1990; 277: 33–36
   PubMed Web of Science ®Google Scholar
• Flegel W A, Wölpl A, Männel D N, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237–2245
   PubMed Web of Science ®Google Scholar
• Warren H S, Riveau G R, De Deckker F A, Chedid L A. Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor. Infect Immun 1988; 6: 204–212
   Google Scholar
• Weinstock C, Ullrich H, Hohe R, Berg A, Baumstark M WW, Frey I, Northoff H, Flegel W A. Low density lipoproteins inhibit endotoxin activation of monocytes. Arteriosclerosis and Thrombosis 1992; 12: 341–347
   PubMedGoogle Scholar
• Mathison J C, Wolfson N, Ulevitch R J. Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925–1937
   PubMed Web of Science ®Google Scholar
• Baumberger C, Ulevitch R J, Dayer J M. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 1991; 59: 378–383
   PubMed Web of Science ®Google Scholar
• Morel D W, DiCorleto P E, Chisolm G M. Modulation of endotoxin-induced endothelial cell toxicity by low density lipoproteins. Lab Invest 1986; 55: 419–426
   PubMed Web of Science ®Google Scholar
• Navab M, Hough G P, Van Lenten B J, Berliner J A, Fogelman A M. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest 1988; 81: 601–605
   PubMed Web of Science ®Google Scholar
• Harris H W, Grunfeld C, Feingold K R, Rapp J H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696–702
   PubMed Web of Science ®Google Scholar
• Harris H W, Grunfeld C, Feingold K R, Read T E, Kane J P, Jones A L, Eichbaum E B, Bland G F, Rapp J H. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91: 1028–1034
   PubMed Web of Science ®Google Scholar
• Ulevitch R J, Johnston A R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest 1978; 62: 1313–1324
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Nikaido H. Physical interaction between Lipid A and phospholipids: a study with spin-labeled phospholipids. Rev Infect Dis 1984; 6: 488–492
   PubMedGoogle Scholar
• Fried V A, Rothfield L I. Interaction between lipopolysaccharide and phosphatidylethanolamine in molecular monolayers. Biochim Biophys Acta 1978; 514: 69–82
   PubMedGoogle Scholar
• Kim Y C, Nishida T. Nature of the interaction of dextran sulfate with high and low density lipoproteins in the presence of Ca2+. J Biol Chem 1979; 254: 9621–9626
   PubMed Web of Science ®Google Scholar
• Toth C A, Thomas P. Liver endocytosis and Kupffer cells. Hepatology 1992; 16: 255–266
   PubMed Web of Science ®Google Scholar
• Tahri-Jouti M A, Chaby R. Binding of endotoxin to macrophages: distinct effects of serum constituents. Immunol Invest 1991; 20: 377–386
   PubMed Web of Science ®Google Scholar
• Freudenberg M A, Galanos C. The metabolic fate of endotoxins. Bacterial endotoxins: pathophysiological effects, clinical significance, and pharmacological control. Alan R Liss Inc., New York 1988; 63–75
   Google Scholar
• Mathison J C, Ulevitch R J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979; 123: 2133–2143
   PubMed Web of Science ®Google Scholar
• Munford R S, Andersen J M, Dietslly J M. Sites of tissue binding and uptake in vivo of bacterial lipopolsaccharide-high density lipoprotein complexes. J Clin Invest 1981; 68: 1503–1513
   PubMed Web of Science ®Google Scholar
• Raetz C RH, Ulevitch R J, Wright S D, Sibley C H, Ding A, Nathan C F. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991; 5: 2652–2660
   PubMed Web of Science ®Google Scholar
• Hampton R Y, Golenbock D T, Penman M, Krieger M, Raetz C RH. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 1991; 352: 342–344
   PubMed Web of Science ®Google Scholar
• Wright S D, Detmers A, Aida Y, Adamowski R, Anderson D C, Chad Z, Kabbash L G, Pabst M J. CD18-deficient cells respond to lipopolysaccharide in vitro. J Immunol 1990; 144: 2566–2571
   PubMed Web of Science ®Google Scholar
• Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann Rev Biochem 1988; 57: 505–518
   PubMed Web of Science ®Google Scholar
• Cerami A. Inflammatory cytokines. Clin Immunol Immunpathol 1992; 62: S3–S10
   PubMedGoogle Scholar
• Spooner C E, Markowitz N P, Saravolatz L D. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopathol 1992; 62: S11–S17
   PubMedGoogle Scholar
• Dinarello C A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrom. J Infect Dis 1991; 163: 1177–1184
   PubMed Web of Science ®Google Scholar
• Freudenberg M A, Galanos C. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. Intern Rev Immunol 1990; 6: 207–221
   PubMedGoogle Scholar
• Xari V P, Steele A S, Davis P J, Buescher E S, Rios C N, Garcia-Bunuel R. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57: 211–221
   PubMed Web of Science ®Google Scholar
• Ross R. Atheroscerosis: a problem of the biology of artery wall cells and their interactions with blood components. Arteriosclerosis 1981; 1: 293–311
   PubMedGoogle Scholar
• Abdelnoor A M, Harvie N R, Johnson A G. Neutralization of bacteria- and endotoxin-induced hypotension by lipoprotein-free human serum. Infect Immun 1982; 38: 157–161
   PubMed Web of Science ®Google Scholar
• Layman D L, Landreneau L A. Suppresion of fibroblast growth by Bacteroides gingivalis endotoxin is not reduced by serum lipoproteins. J Periodontol 1989; 60: 59–263
   Web of Science ®Google Scholar
• Warren H S, Knight C V, Siber G R. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J Infect Dis 1986; 154: 784–791
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Mori K, Gans H, Akagi M. Endotoxin inactivation by the humoral components in the tolerant rat serum. Toxicology 1987; 4: 257–268
   Google Scholar
• Sakaguchi S. Metabolic disorders of serum lipoproteins in endotoxin-poisoned mice: the role of high density lipoprotein (HDL) and triglyceride-rich lipoproteins. Microbiol Immunol 1982; 26: 1017–1034
   PubMed Web of Science ®Google Scholar
• Skarnes R C, Chedid L C. Biological degradation and inactivation of endotoxin. Bacterial endotoxin, M Landy, W Braun. Rutgers University Press, New Brunswick, New Jersey 1964; 575–587
   Google Scholar
• Skarnes R C. The inactivation of endotoxin after interaction with certain proteins of normal serum. Ann NY Acad Sci 1966; 133: 644–662
   PubMed Web of Science ®Google Scholar
• Moreau S C. Skarmes. Host resistance to bacterial endotoxemia: mechanisms in endotoxin-tolerant animals. J Infect Dis 1973; 128: S122–S133
   Web of Science ®Google Scholar
• Berger D, Beger H G. Endotoxin binding proteins of human serum: are there therapeutic implications?. Surg Res Commun 1990; 8: 147–156
   Google Scholar
• Liao W, Jin X Y, Cui X S, Li X Y, Zhao E Z, Bai W T. The effect of plasma fibronectin on endotoxin activity. Clin J Immunol 1988; 4: 377
   Google Scholar
• Munford R S, Dietschy J M. Effects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis 1985; 52: 177–184
   Google Scholar
• Tobias P S, Ulevitch R J. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J Immunol 1983; 131: 1913–1916
   PubMed Web of Science ®Google Scholar
• Tobias P S, McAdam K PWJ, Soldau K, Ulevitch R J. Control of lipopolysaccharide-high density lipoprotein interactions by an acute-phase reactant in human serum. Infect Immun 1985; 50: 73–76
   PubMed Web of Science ®Google Scholar
• Ramadori G, Meyer zum Buschenfelde K H, Tobias P S, Mathison J C, Ulevitch R J. Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocytes. Pathobiology 1990; 58: 89–94
   PubMed Web of Science ®Google Scholar
• Tobias P S, Soldau K, Ulevitch R J. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989; 264: 10867–10871
   PubMed Web of Science ®Google Scholar
• Wright S D, Ramos R A, Tobias P S, Ulevitch R J, Mathison J C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431–1433
   PubMed Web of Science ®Google Scholar
• Mathison J, Tobias P, Wolfson E, Ulevitch R. Regulatory mechanisms of host responsiveness to endotoxin (lipopolysaccharide). Pathobiology 1991; 59: 185–188
   PubMed Web of Science ®Google Scholar
• Mathison J C, Tobias P S, Wolfson E, Ulevitch R J. Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of Gram-negative LPS. J Immunol 1992; 149: 200–206
   PubMed Web of Science ®Google Scholar
• Munford R S, Hall C L. Purification of acyloxyacyl hydrolase, a leukocyte enzyme that removes secondary acyl chains from bacterial lipopolysaccharides. J Biol Chem 1989; 264: 15613–15619
   PubMed Web of Science ®Google Scholar
• Wright S D, Ramos R A, Patel M, Miller D S. Septin: a factor in plasma that opsonizes lipopoly-saccharide-bearing particles for recognition by CD14on phagocytes. J Exp Med 1992; 176: 719–727
   PubMed Web of Science ®Google Scholar
• Sernatinger J, Hoffman A, Harman D, Kane J P, Levy J A. Neutralization of mouse xenotropic virus by lipoproteins involves binding to the virions. J Gen Virol 1988; 69: 2651–2661
   Web of Science ®Google Scholar
• Chisari F V, Curtiss L K, Jensen F C. Physiological concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus. J Clin Invest 1981; 68: 329–336
   PubMed Web of Science ®Google Scholar
• Seganti L, Grassi M, Mastromarino P, Pana A, Superti F, Orsi N. Activity of human serum lipoproteins on the infectivity of rhabdoviruses. Microbiologica 1983; 6: 91–99
   PubMedGoogle Scholar
• Shortridge K F, Ho W K, Oya A, Kobayashi M. Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asia J Trop Med Public Health 1975; 6: 461–466
   PubMedGoogle Scholar
• Bhakdi S, Tranum-Jensen J, Utermann G, Fussle R. Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human low density lipoprotein. J Biol Chem 1983; 258: 5899–5904
   PubMed Web of Science ®Google Scholar